Meeting
2017 ASCO Annual Meeting
Implementation of Modern Eligibility in Trials: Industry Perspective
Presenter
Eric H. Rubin, MD
Merck Research Laboratories
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Education Session
Session Title
Strategies to Maximize Patient Participation in Clinical Trials
Track
Developmental Therapeutics and Translational Research,Clinical Trials,Pediatric Oncology,Disparities/Health Equity,Geriatric Oncology
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.
Speaker: Martin H. Schuler, MD
Videos & Slides
2024 ASCO Annual Meeting
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.
Speaker: Syed A. Hussain, MD
Videos & Slides
2023 ASCO Annual Meeting
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.
Speaker: Patricia Marinello, PharmD
Videos & Slides
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
Speaker: Jianqing Zhu, MD